OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Singapore Budget 2026 Set for Fiscal Prudence as Growth Remains Resilient 
China Extends Gold Buying Streak as Reserves Surge Despite Volatile Prices 
NASA Partners with Katalyst to Save Swift Observatory with Innovative Docking Mission 
SpaceX Starship Explodes in Texas During Test, Citing Nitrogen Tank Failure 
Gold and Silver Prices Slide as Dollar Strength and Easing Tensions Weigh on Metals 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock 
U.S.-India Trade Framework Signals Major Shift in Tariffs, Energy, and Supply Chains 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate 
Trump Signs Executive Order to Boost AI Research in Childhood Cancer 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Sanofi Gains China Approval for Myqorzo and Redemplo, Strengthening Rare Disease Portfolio 
SpaceX’s Starship Completes 11th Test Flight, Paving Way for Moon and Mars Missions 
JW Pharmaceutical will use the zebrafish to develop new drugs and expand indications of its drug candidates.
To expedite the process, the South Korean drug developer has inked a memorandum of understanding (MOU) with Zefit, a domestic non-clinical trial institute that specializes in zebrafish models.
Zefit will provide disease-specific zebrafish models using gene editing technology and a drug screening platform.
Zebrafish, a tropical fish species whose genetic structure is more than 80 percent similar to humans, is increasingly being used as a non-clinical intermediary research model.
Zebrafish can replace mammalian experiments, according to Zefit.
Conducting experiments with zebrafish can bring down costs to about one-tenth of those for mammals.
JW Pharmaceutica plans to use zebrafish to bridge the gap between non-clinical and clinical research.
Zebrafish experiments can be 91 percent similar to those conducted with mammals.
According to Shin Jun-nyeong, CEO of Zefit, Interest in zebrafish is increasing among regulatory agencies such as the US Food and Drug Administration (FDA).
